Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187184 · ClinicalTrials.gov registry record · NA
Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic
A NA study, sponsored by Essentia Health.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03187184 is a NA study that has completed, run by Essentia Health. The registered enrollment target is 40 participants.
The verdict
NCT03187184, a NA study, has completed, sponsored by Essentia Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Pharmacogenomics (PGx) studies the interactions between an individuals genes and medications. PGx testing identifies genes within an individual that may affect treatment, efficacy, and toxicity of drugs. With improvements in testing speed, accuracy and cost, it is now possible to perform PGx testing in cancer patients prior to starting chemotherapy. The test results may help a physician personalize chemotherapy dosing. The goal of this study is to determine if PGx testing using the OneOme® Rightmed test is feasible in a community oncology clinic to guide treatment prior to starting chemotherapy. The study will also gather data regarding the frequency of genes within the local population as well as the impact of testing on chemotherapy doses.
Interventions
- DEVICE OneOme RightMed®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-05-20 |
| Est. Completion | 2019-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03187184
The ClinicalTrials.gov registry entry for NCT03187184 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essentia Health, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OneOme RightMed® is the first listed.
NCT03187184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03187184 about?
NCT03187184 is a clinical study titled "Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic". Pharmacogenomics (PGx) studies the interactions between an individuals genes and medications. PGx testing identifies genes within an individual that may affect treatment, efficacy, and toxicity of drugs. With improvements in testing speed, accuracy and cost, it is now possible to perform PGx testing...
What is the current status of trial NCT03187184?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2017-05-20. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT03187184?
The interventions under investigation include: OneOme RightMed® (DEVICE).
Who is sponsoring clinical trial NCT03187184?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.